fool.com · 14 jul

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity holdings.

zacks.com · 10 jul

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

fool.com · 7 jul

iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?

IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.

globenewswire.com · 7 jul

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

investors.com · 26 jun

Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs

Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.

247wallst.com · 25 jun

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.

globenewswire.com · 17 jun

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment.

zacks.com · 17 jun

Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.